Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 97; no. 2; pp. 157 - 159
Main Author HANTSCHEL, Oliver
Format Journal Article
LanguageEnglish
Published Pavia Ferrata Storti Foundation 01.02.2012
Subjects
Biological and medical sciences
Chromosome aberrations
Fusion Proteins, bcr-abl - antagonists & inhibitors
Hematologic and hematopoietic diseases
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical genetics
Medical sciences
Pyrimidines - pharmacology
Chromosomal aberration
Drug combination
Treatment resistance
Philadelphia positive acute lymphoblastic leukemia
Hematology
Enzyme
Transferases
Non-specific serine/threonine protein kinase
Malignant hemopathy
Philadelphia chromosome
Abnormal chromosome C9
Allosteric inhibitor
bcr gene
Lymphoproliferative syndrome
C-Onc gene
Abnormal chromosome G22
Abnormal chromosome
Hybrid gene
Cancer
Chromosome translocation
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2012.061812